"166663-25-8"@en . . . "V-Echinocandin"@en . . . . "# Cappelletty D, Eiselstein-McKitrick K: The echinocandins. Pharmacotherapy. 2007 Mar;27(3):369-88. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17316149 # Vazquez JA: Anidulafungin: a new echinocandin with a novel profile. Clin Ther. 2005 Jun;27(6):657-73. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16117974 # Grover ND: Echinocandins: A ray of hope in antifungal drug therapy. Indian J Pharmacol. 2010 Feb;42(1):9-11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20606829 # Vazquez JA: The safety of anidulafungin. Expert Opin Drug Saf. 2006 Nov;5(6):751-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17044802 # Menichetti F: Anidulafungin, a new echinocandin: effectiveness and tolerability. Drugs. 2009;69 Suppl 1:95-7. doi: 10.2165/11315570-000000000-00000. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19877741 # Vazquez JA, Sobel JD: Anidulafungin: a novel echinocandin. Clin Infect Dis. 2006 Jul 15;43(2):215-22. Epub 2006 Jun 9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16779750 # Estes KE, Penzak SR, Calis KA, Walsh TJ: Pharmacology and antifungal properties of anidulafungin, a new echinocandin. Pharmacotherapy. 2009 Jan;29(1):17-30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19113794 # Morace G, Borghi E, Iatta R, Montagna MT: Anidulafungin, a new echinocandin: in vitro activity. Drugs. 2009;69 Suppl 1:91-4. doi: 10.2165/11315560-000000000-00000. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19877740"@en . . . . . "Candida albicans and other yeasts"@en . . . . . . . . "84%"@en . . . "(4R,5R)-4,5-Dihydroxy-N\u00B2-[[4''-(pentyloxy)-p-terphenyl-4-yl]carbonyl]-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4(p-hydroxyphenyl)-L-threonyl-L-threonyl-(3S,4S)-3-hydroxy-4-methyl-L-proline cyclic (6->1)-peptide"@en . "approved"@en . "Scott Jenkins, Gary Liversidge, Deborah Neville, \"Nanoparticulate Anidulafungin Compositions and Methods for Making the Same.\" U.S. Patent US20090238867, issued September 24, 2009."@en . "Anidulafungin"@en . "Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin. [Wikipedia]"@en . . . "* 1 L/h"@en . " "@en . . . "Anidulafungine"@en . . . "Aspergillis, Candida and other fungi"@en . "Anidulafungin"@en . "Coolia tropicalis"@en . . "Anidulafungina"@en . . . . . . . . "N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2R)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.09,13]heptacosan-18-yl]- 4-{4-[4-(pentyloxy)phenyl]phenyl}benzamide"@en . "For use in the treatment of the following fungal infections: Candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis), Aspergillus infections, and esophageal candidiasis. Also considered an alternative treatment for oropharyngeal canaidiasis."@en . . . "* 30 to 50 L"@en . "Less than 1% of the administered radioactive dose was excreted in the urine. Anidulafungin is not hepatically metabolized."@en . . "40-50 hours"@en . . . "Eraxis"@en . . . . . . . "Anidulafunginum"@en . . . . " Candida parapsilosis"@en . "During clinical trials a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose. No clinical adverse events were reported. The maximum non-lethal dose of anidulafungin in rats was 50 mg/kg, a dose which is equivalent to 10 times the recommended daily dose for esophageal candidiasis (50mg/day)."@en . "investigational"@en . . . . . . "Anidulafungin is a semi-synthetic echinocandin with antifungal activity. Anidulafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3-β-D-glucan, an essential component of the fungal cell wall, ultimately leading to osmotic instability and cell death."@en . . . . .